US OptionsDetailed Quotes
ZYME250117C15000
- 0.64
- +0.04+6.67%
15min DelayClose Jan 2 16:00 ET
0.64High0.59Low
0.60Open0.60Pre Close10 Volume219 Open Interest15.00Strike Price619.00Turnover55.49%IV5.82%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.64Extrinsic Value100Contract SizeAmericanOptions Type0.4764Delta0.2396Gamma25.70Leverage Ratio-0.0232Theta0.0027Rho12.25Eff Leverage0.0119Vega
Zymeworks Stock Discussion
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Inc. (Nasdaq: ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW191, a novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). ZW191 targets FR⍺-expressing tumors, including ovarian, gynecological cancers, and non-small...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks (Nasdaq: ZYME) announced that the FDA has cleared its investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody designed to treat mesothelin (MSLN)-expressing cancers such as ovarian cancer, non-small cell lung cancer, and mesothelioma. ZW171 aims to i...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
youtube.com/emb...
$Abbott Laboratories (ABT.US)$ $Agrify (AGFY.US)$ $Tesla (TSLA.US)$ $Amprius Technologies (AMPX.US)$ $Olaplex (OLPX.US)$ $Momentive Global (MNTV.US)$ $SOBR Safe (SOBR.US)$ $Zymeworks (ZYME.US)$ $Generac (GNRC.US)$ $Netflix (NFLX.US)$
No comment yet